Cargando…

Longitudinal changes in serum adropin levels and liver fat content during liraglutide treatment in newly diagnosed patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease

AIMS: To explore the effect of liraglutide treatment on serum adropin and its relationship to the liver fat content in newly diagnosed patients with type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated fatty liver disease (MAFLD). METHODS: Serum adropin level and liver fat content we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Lin, Wu, Xiaojuan, Li, Xinyue, Chang, Xiaona, Ding, Xiaoyu, Wang, Qiu, Jiang, Tao, Wang, Guang, Liu, Jia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198855/ https://www.ncbi.nlm.nih.gov/pubmed/37079136 http://dx.doi.org/10.1007/s00592-023-02082-3

Ejemplares similares

Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
por: Li, Xinyue, et al.
Publicado: (2021)

Regulation of Adropin by Sitagliptin monotherapy in participants with newly diagnosed type 2 Diabetes
por: Wang, Qiu, et al.
Publicado: (2022)

Serum Adropin as a Potential Biomarker for Predicting the Development of Type 2 Diabetes Mellitus in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease
por: Li, Na, et al.
Publicado: (2021)

ADROPIN – POTENTIAL LINK IN CARDIOVASCULAR PROTECTION FOR OBESE MALE TYPE 2 DIABETES MELLITUS PATIENTS TREATED WITH LIRAGLUTIDE
por: Tičinović Kurir, Tina, et al.
Publicado: (2020)

Association between Intrapancreatic Fat Deposition and Lower High-Density Lipoprotein Cholesterol in Individuals with Newly Diagnosed T2DM
por: Wang, Jianliang, et al.
Publicado: (2023)

Association of Circulating TXNIP Levels with Fatty Liver in Newly Diagnosed Type 2 Diabetes Mellitus
por: Guo, Yuting, et al.
Publicado: (2022)

Efficacy and Clinical Value of Liraglutide for Treatment of Diabetes Mellitus Complicated by Non-Alcoholic Fatty Liver Disease
por: Zhang, Zhongyong, et al.
Publicado: (2018)

Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease
por: Tian, Feng, et al.
Publicado: (2018)

ERα-Dependent Regulation of Adropin Predicts Sex Differences in Liver Homeostasis during High-Fat Diet
por: Meda, Clara, et al.
Publicado: (2022)

Liraglutide Attenuates Nonalcoholic Fatty Liver Disease by Modulating Gut Microbiota in Rats Administered a High-Fat Diet
por: Zhang, Ningjing, et al.
Publicado: (2020)

The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
por: Ohki, Takamasa, et al.
Publicado: (2012)

Liraglutide with Lifestyle Intervention in Adolescents with Overweight/Obesity, Nonalcoholic Fatty Liver Disease, and Type II Diabetes Mellitus
por: Kohut, Taisa, et al.
Publicado: (2021)

THE RELATION BETWEEN THE FAT CONTENT OF THE BILE AND FATTY CHANGES IN THE LIVER
por: Le Count, Edwin R., et al.
Publicado: (1914)

Adipose tissue dysfunction increases fatty liver association with pre diabetes and newly diagnosed type 2 diabetes mellitus
por: Jorge-Galarza, Esteban, et al.
Publicado: (2016)

Noninvasive Quantitative Detection Methods of Liver Fat Content in Nonalcoholic Fatty Liver Disease
por: Lv, Shujing, et al.
Publicado: (2018)

Effects of Liraglutide on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: Song, Tiantian, et al.
Publicado: (2021)

Fat content, fatty acid pattern and iron content in livers of turkeys with hepatic lipidosis
por: Visscher, Christian, et al.
Publicado: (2017)

Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids
por: Orešič, Matej, et al.
Publicado: (2013)

Improving the accuracy of fatty liver index to reflect liver fat content with predictive regression modelling
por: Asaturyan, Hykoush A., et al.
Publicado: (2022)

Fatty liver index correlates with non-alcoholic fatty liver disease, but not with newly diagnosed coronary artery atherosclerotic disease in Chinese patients
por: Jiang, Zhao-Yan, et al.
Publicado: (2013)

Fasting plasma adropin concentrations correlate with fat consumption in human females
por: St-Onge, Marie-Pierre, et al.
Publicado: (2013)

Liraglutide on type 2 diabetes mellitus with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 16 RCTs
por: Zhao, Yan, et al.
Publicado: (2023)

One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial
por: Vedtofte, Louise, et al.
Publicado: (2020)

Varied Relationship of Lipid and Lipoprotein Profiles to Liver Fat Content in Phenotypes of Metabolic Associated Fatty Liver Disease
por: Wu, Tingfeng, et al.
Publicado: (2021)

Variation in fat content between liver lobes and comparison with histopathological scores in dairy cows with fatty liver
por: Gerspach, C., et al.
Publicado: (2017)

Lipoprotein Insulin Resistance Index Reflects Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease
por: Vittal, Anusha, et al.
Publicado: (2020)

Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis
por: Guo, Tingli, et al.
Publicado: (2023)

Dietary Composition and Its Association with Newly Diagnosed Nonalcoholic Fatty Liver Disease and Insulin Resistance
por: Charatcharoenwitthaya, Phunchai, et al.
Publicado: (2021)

The Hepatokine Adropin Is Regulated by Estrogen
por: Stokar, Joshua, et al.
Publicado: (2021)

Clinical characteristics of patients with diabetes mellitus and fatty liver diagnosed by liver/spleen Hounsfield units on CT scan
por: Sakitani, Kosuke, et al.
Publicado: (2017)

The Effect of Empagliflozin on Liver Fat in Type 2 Diabetes Mellitus Patients With Non-Alcoholic Fatty Liver Disease
por: Pokharel, Arbinda, et al.
Publicado: (2021)

Therapeutic efficacy of liraglutide versus metformin in modulating the gut microbiota for treating type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease
por: Ying, Xing, et al.
Publicado: (2023)

Adropin protects against liver injury in nonalcoholic steatohepatitis via the Nrf2 mediated antioxidant capacity
por: Chen, Xu, et al.
Publicado: (2018)

Comparison of Serum Adropin Levels in Patients with Diabetes Mellitus, COVID-19, and COVID-19 with Diabetes Mellitus
por: Aydın, Pelin, et al.
Publicado: (2022)

Correlation of multiple lipid and lipoprotein ratios with nonalcoholic fatty liver disease in patients with newly diagnosed type 2 diabetic mellitus: A retrospective study
por: Li, Ran, et al.
Publicado: (2023)

Adropin as A Fat-Burning Hormone with Multiple Functions—Review of a Decade of Research
por: Jasaszwili, Mariami, et al.
Publicado: (2020)

Visceral Fat Thickness Predicts Fatty Liver in Koreans with Type 2 Diabetes Mellitus
por: Kim, Hai Jin, et al.
Publicado: (2008)

Newly Diagnosed Idiopathic Liver Abscess: Colonoscopy Required!
por: Makkar, Priyanka, et al.
Publicado: (2017)

Liver pathology in children with newly diagnosed celiac disease
por: Kwiatek-Średzińska, Kamila Agnieszka, et al.
Publicado: (2019)

Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction
por: Ye, Junzhao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_53maq4qt4jlqifst8nd8bf2o69